{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:54:33Z","timestamp":1792619673902,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.04.016","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:55:24Z","timestamp":1752616524000},"page":"1020-1029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair\u2013deficient Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"Sandra","family":"van Wilpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Rothmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellery","family":"Altshuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa M.","family":"Ledet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rothermundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelieke E.C.A.B.","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Tsantoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bernard-Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie G.J.","family":"Robbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl P.","family":"Bruijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van der Hulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00f6nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.016_b0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0010","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0020","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.04.016_b0030","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0035","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/s41467-019-13084-7","article-title":"The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact","volume":"10","author":"van Dessel","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2025.04.016_b0040","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0045","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s43018-021-00227-3","article-title":"Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression","volume":"2","author":"Lopez-Bujanda","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.euo.2025.04.016_b0050","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.euo.2025.04.016_b0055","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00262-022-03347-6","article-title":"Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients","volume":"72","author":"Fang","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euo.2025.04.016_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233260","article-title":"Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies","volume":"15","author":"Graham","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2025.04.016_b0065","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1002\/onco.13601","article-title":"Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer","volume":"26","author":"Sena","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2025.04.016_b0070","article-title":"Pan-cancer prevalence of microsatellite instability-high (MSI-H) identified by circulating tumor DNA and associated real-world clinical outcomes","volume":"7","author":"Kasi","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41391-024-00799-y","article-title":"A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and\/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis","volume":"28","author":"Mosalem","year":"2025","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2025.04.016_b0080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.016_b0085","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","volume":"8","author":"Barata","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2025.04.016_b0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.5394","article-title":"Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer","volume":"5","author":"Graf","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.04.016_b0095","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1200\/PO.20.00209","article-title":"Responsiveness to immune checkpoint inhibitors is associated with a peripheral blood T-cell signature in metastatic castration-resistant prostate cancer","volume":"4","author":"Simnica","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.19.00818","article-title":"Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from Arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study","volume":"38","author":"Azad","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2023.100003","article-title":"Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN","volume":"1","author":"Mishima","year":"2023","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.euo.2025.04.016_b0110","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-24-0480","article-title":"The innate immune landscape of dMMR\/MSI cancers predicts outcome of nivolumab treatment: results from the Drug Rediscovery Protocol","volume":"30","author":"Zeverijn","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.016_b0115","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.016_b0120","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0125","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.04.016_b0130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.04.016_b0135","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/jnci\/djad063","article-title":"Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome","volume":"115","author":"Elze","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2025.04.016_b0140","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3390\/cancers11101567","article-title":"Microsatellite instability: diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer","volume":"11","author":"Evrard","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.04.016_b0145","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.euo.2025.04.016_b0150","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1373\/clinchem.2014.223677","article-title":"Microsatellite instability detection by next generation sequencing","volume":"60","author":"Salipante","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.euo.2025.04.016_b0155","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jmoldx.2017.11.007","article-title":"A novel and reliable method to detect microsatellite instability in colorectal cancer by next-generation sequencing","volume":"20","author":"Zhu","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.euo.2025.04.016_b0160","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-19-1324","article-title":"Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel","volume":"25","author":"Willis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.016_b0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40425-018-0341-y","article-title":"Microsatellite instability in prostate cancer by PCR or next-generation sequencing","volume":"6","author":"Hempelmann","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2025.04.016_b0170","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1172\/JCI121924","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Rodrigues","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euo.2025.04.016_b0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13073-018-0595-5","article-title":"Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis","volume":"10","author":"Mayrhofer","year":"2018","journal-title":"Genome Med"},{"key":"10.1016\/j.euo.2025.04.016_b0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2353\/jmoldx.2008.080031","article-title":"Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part I. The utility of immunohistochemistry","volume":"10","author":"Shia","year":"2008","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.euo.2025.04.016_b0185","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1097\/PAS.0b013e3181f906cc","article-title":"Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma","volume":"34","author":"Bao","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euo.2025.04.016_b0190","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/PAS.0b013e31816401bb","article-title":"Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting","volume":"32","author":"Overbeek","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euo.2025.04.016_b0195","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.04.016_b0200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2023.03.029","article-title":"Tumour mutational burden as a biomarker in patients with mismatch repair deficient\/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors","volume":"187","author":"Manca","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:22:08Z","timestamp":1758079328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001099"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.016","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair\u2013deficient Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}